Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 186, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2022.109781
Keywords
Sodium glucose cotransport; Fat mass; Muscle mass; Non-alcoholic fatty liver disease; Nuclear magnetic resonance spectroscopy; Amino acid
Categories
Funding
- AstraZeneca
- Ono Pharmaceutics
Ask authors/readers for more resources
This study aimed to investigate the effects of the SGLT2 inhibitor dapagliflozin on body composition and amino acid metabolism. The results showed that dapagliflozin treatment significantly reduced body weight and fat mass, while maintaining fat-free mass. In addition, it also reduced intrahepatic triglyceride content. Changes in amino acids were minimal, with only a significant reduction in serine concentrations observed.
Aim: We aimed to determine whether SGLT2 inhibitor dapagliflozin treatment affects body composition and amino acid (AA) metabolism. Methods: Fifty-two overweight patients treated by oral antidiabetic agents were randomly assigned to dapagliflozin (Dapa) or a standard treatment (Con) and followed for 24 weeks. The primary outcome was the change in body mass (BM) between baseline and week 24. Body composition, intrahepatic triglyceride (IHTG) content, and plasma AA concentrations were examined as secondary outcomes. Results: The change in BM was significantly larger in the Dapa than in the Con group, with a difference in the mean change of-1.72 kg (95 %CI:-2.85,-0.59; P = 0.004) between the groups. Total fat mass was reduced by dapagliflozin treatment, but fat-free mass was maintained. IHTG content was significantly reduced in the Dapa than in the Con (P = 0.033). Changes in AAs showed small differences between the groups, but only serine concentrations were significantly reduced in the Dapa. Intra-group analysis showed that positive associations were observed between changes in branched chain AA concentrations and body composition only in the Dapa. Conclusions: Dapagliflozin treatment causes a reduction in BM mainly by reducing fat mass. AA metabolism shows subtle changes with dapagliflozin treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available